Australia markets closed

Aptinyx Inc. (APTX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
0.4451+0.0231 (+5.47%)
At close: 04:00PM EDT
0.4550 +0.01 (+2.22%)
After hours: 07:04PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close0.4220
Open0.4730
Bid0.4449 x 1300
Ask0.4550 x 1300
Day's range0.4290 - 0.4730
52-week range0.3600 - 3.7600
Volume425,369
Avg. volume549,869
Market cap30.14M
Beta (5Y monthly)1.49
PE ratio (TTM)N/A
EPS (TTM)-1.1900
Earnings date08 Aug 2022 - 12 Aug 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est4.67
  • Business Wire

    Aptinyx to Participate in H.C. Wainwright 1st Annual Mental Health Conference

    EVANSTON, Ill., June 22, 2022--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced that company management will present at the H.C. Wainwright 1st Annual Mental Health Conference. The conference is being held at the Lotte New York Palace Hotel and virtually from June 27–28, 2022.

  • Business Wire

    Aptinyx to Participate in H.C. Wainwright Global Investment Conference

    EVANSTON, Ill., May 18, 2022--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced that company management will present at the H.C. Wainwright Global Investment Conference to be held May 23-26, 2022. The presentation will be available on-demand through the H.C. Wainwright conference portal, beginning at 7:00 AM ET on Tuesday, May 24, 2022.

  • Business Wire

    Aptinyx Announces Poster Presentation Highlighting Preclinical Data on NYX-783 in Models of PTSD at the 2022 American Psychiatric Association Annual Meeting

    EVANSTON, Ill., May 17, 2022--Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that data from preclinical studies of NYX-783 in models of post-traumatic stress disorder (PTSD) will be presented in a poster at the American Psychiatric Association Annual Meeting being held May 21 – 25, 2022 in New Orleans, LA.